At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Double-Blind, Randomized, Placebo-Controlled Phase 2 Study to Investigate the Safety and Efficacy of 0.1% and 1.0% Topically Applied GLYC-101, Compared to Placebo, in Patients Undergoing Carbon Dioxide Laser Skin Resurfacing of the Lower Eyelids.
In Brief
A Phase 2 clinical trial evaluating GLYC-101 Gel (0.1%), GLYC-101 Gel (1.0%), and 1 other intervention for Wounds. Completed, enrolled 26 participants across 1 site.
Detailed Summary
The primary objectives of this study are to evaluate safety and efficacy of topically applied Glucoprime gel (GLYC-101, 0.1% and GLYC-101, 1.0%) in promoting wound healing in cosmetic surgery patients undergoing Carbon Dioxide Laser Skin Resurfacing (CO2 LSR) of the lower eyelids. The study will observe the effects of the topical agent over the course of 1 month following the initial treatment.
Study Details
Timeline
Interventions
Topical administration to the laser-ablated area on days 1 (day of laser ablation), 2, 3, 4, and 5.
Topical administration to the laser-ablated area on days 1 (day of laser ablation), 2, 3, 4, and 5.
Topical administration to the laser-ablated area on days 1 (day of laser ablation), 2, 3, 4, and 5.